Clinical Trials Logo
  1. Home
  2. Fatty Liver Disease
  3. NCT06071923
  4. Details
NCT06071923 Clinical Trial

Effect of Thyroid Disorders in Liver Diseases

Fatty Liver Disease Clinical Trial

Official title:
Effect of Thyroid Disorders in Metabolic Fatty Liver Changes

Clinical Trial Details — Status: Not yet recruiting

Administrative data
NCT number NCT06071923
Other study ID # 04-2023-200396
Secondary ID
Status Not yet recruiting
Phase
First received
Last updated
Start date January 1, 2024
Est. completion date February 2025

Study information
Verified date October 2023
Source Assiut University
Contact Tasneem Mohammed Ali, Master
Phone 01098704665
Email Tonamohammed96@gmail.com
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Aims of the Research 1. To detect correlation between hyperthyroidism and non alcoholic fatty liver disease (NAFLD). 2. To detect hepatic risk in subclinical and clinical hypothyroidism . 3. To detect early liver disorders in thyroid disorders using fibroscan .

Description:

Non alcoholic fatty liver disease (NAFLD) has been a health problem of growing significance all over the world; its prevalence is increasing in both developed and developing countries ,the overall prevalence of NAFLD worldwide was estimated to be 32.4%.prevalence increased significantly over time. considering the increasing incidence of NALAD/NASH, especially in developed and developing countries, it is anticipated that cirrhosis due to these conditions may exceed other causes of cirrhosis in a near future.. Thyroid gland is involved in energy homeostasis, lipid and carbohydrate metabolism, regulation of body weight and adipogenesis. In a clinical setting, subclinical hypothyroidism has been associated with metabolic syndrome, cardiovascular mortality and disturbance of lipid metabolism. The prevalence of hypothyroidism was reported to 16.8% among patients with NAFLD/NASH. In recent years, growing body of evidence has led to speculation on the association between NAFLD/NASH and thyroid dysfunction. Therefore, understanding the pathophysiology, risk factors and new treatment options of NAFLD/NASH should be among the priorities in the field of hepatology

Recruitment information / eligibility
Status Not yet recruiting
Enrollment 140
Est. completion date February 2025
Est. primary completion date January 1, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: - The study will include thyroid patients over one year duration ( age above 18 years old Exclusion Criteria: 1. History of liver failure or patient known to have congenital liver disease. 2. Medications associated with weight gain . 3. Patients who have diabetes mellitus. 4. patients who already have liver disease eg; chronic viral hepatitis, liver cirrhosis. 5. Patients on antistatin.

Study Design

Related Conditions & MeSH terms

Intervention

Device:
• Fibroscan
Scan the liver for metabolic fatty changes

Locations
Country Name City State
n/a

Sponsors (1)
Lead Sponsor Collaborator
Assiut University

Outcome
Type Measure Description Time frame Safety issue
Primary Detect correlation between hyperthyroid diseases and NASH . Test the patients of thyroid disorders for metabolic fatty liver changes Baseline
See also
  Status Clinical Trial Phase
Recruiting NCT05881005 - NAC- NAFLD And Cushing N/A
Recruiting NCT05220956 - Impact of Time-restricted Feeding in NAFLD N/A
Enrolling by invitation NCT04066608 - Prevalence of Advanced Fibrosis in Patients Living With HIV
Recruiting NCT04302051 - Assessment of Fatty Liver With Thermo-acoustic Device
Recruiting NCT04496895 - The Evaluation of Orange Peel Fermentation on Body Fat Lowering Efficacy in Adults N/A
Recruiting NCT05880316 - Prevalence of MAFLD Among Nurses and the Role of Intermittent Fasting N/A
Active, not recruiting NCT05898841 - Study to Evaluate the Efficacy and Safety of a Rilpivarine-based Antiretroviral Tratment Regimen in HIV- Infected Patients With Liver Metabolic Disease Who Maintain Udetectable HIV Viral Load Phase 4
Completed NCT05764811 - SGLT-2 Inhibitor Effects on Cardiac and Hepatic Metabolic Profiles for the Diabetes Patients Combined With Obesity N/A
Active, not recruiting NCT05076058 - Effects of Tablets of Silybum Marianum, Pueraria Lobate and Salvia Miltiorrhiza on Fatty Liver N/A
Recruiting NCT05421572 - Epidemiological Survey on Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)
Recruiting NCT06302049 - Clinical Study Evaluating the Safety and Efficacy of Esomeprazole in Treatment of Non-alcoholic Steatohepatitis Phase 1/Phase 2
Completed NCT04283942 - Effect of Intermittent Calorie Restriction on MASLD Patients With Abnormal Glucose Metabolism N/A
Completed NCT01016418 - Bovine Colostrum for Patients With Non Alcoholic Fatty Liver Disease Phase 1/Phase 2
Terminated NCT04175392 - Effect of Probiotics in Non-alcoholic Fatty Liver Disease and Steatohepatitis Phase 1/Phase 2
Not yet recruiting NCT04191044 - Portal Hypertension in Non-alcoholic Fatty Liver Disease: Association With Cardiovascular Risk and Identification of Non-invasive Biomarkers (THESIS)
Recruiting NCT04525833 - Liver Disease and Other Systemic Diseases
Not yet recruiting NCT05966025 - Potential Benefits of Itopride in the Management of Patients With Metabolic Associated Fatty Liver Disease (MAFLD) Phase 2
Completed NCT04844450 - A Single and Multiple Ascending Dose Study of Subcutaneously Administered JNJ-75220795 Phase 1
Completed NCT04367012 - Fatty Liver Among Employees at Banha University
Completed NCT05694923 - Effect of Sodium Glucose Cotransporter Inhibitors on Non Diabetic Fatty Liver Disease Patients N/A